 
 
C O N F I D E N T I A L  
Zosano Pharma  [ADDRESS_308097]  Fremont, CA [ZIP_CODE]  
 
CLINICAL PROTOCOL  
 
STUDY TITLE:  A Randomized O pen-label F our-way C rossover S tudy to C ompare 
the P harmacokinetics, S afety, and Tolerability of Three D ifferent 
Formulations of M207 3.8 mg ( Administered as two 1.9 mg 
patches)  on the Upper arm  for 30 M inutes  with Intranasal 
Zolmitriptan 2.5 mg  in H ealthy Volunteers  
PROTOCOL NUMBER:  CP-2019- 002 
PROTOCOL VERSION:  1.0  
PROTOCOL DATE:  15 April 2019 
STUDY DRUG:   M207 (Zolmitriptan  Microneedle System ) 
SPONSOR:  Zosano Pharma  Corporation 
[ADDRESS_308098] :  Peter Schmidt, MD , MSc  
[ADDRESS_308099]  
Fremont, CA [ZIP_CODE]  
[LOCATION_002]  
 
 
 
This document is a confidential communication of Zosano Pharma. The recipi[INVESTIGATOR_253300], except that this document may be disclosed to appropri ate institutional review 
boards or duly authorized representatives of the US Food and Drug Administration (FDA) or other regulatory agencies under the condition that they are asked to maintain confidentiality.  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
[ADDRESS_308100]  
IV Intravenous  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 4 of 69 
 Abbreviation  Definition  
J Joules  
k Apparent elimination rate constant  
kg Kilogram  
KIU Kilo international units  
µg Microgram  
L Liter  
LDH  Lactate dehydrogenase  
µm Micrometer  
M207  Zolmitriptan  Microneedle System (M207)  
MedDRA® Medical Dictionary for Regulatory Activities  
mL Milliliters  
mmol  millimole(s)  
NSAID  Nonsteroidal anti -inflammatory drug  
PD Pharmacodynamics  
PE Physical examination  
PK Pharmacokinetics  
PPI [INVESTIGATOR_253301]  
t½ Apparent half life  
TEAE  Treatment -emergent adverse event  
Tmax Time to maximum concentration  
WHO  World Health Organization  
ZP Zosano Pharma  
 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
[ADDRESS_308101] OF ABBREVIATION S AND DEFINITION OF TERMS  .............................................. 3 
TABLE OF CONTENTS  ............................................................................................................. 5 
PROTOCOL SYNOPSIS  ............................................................................................................. 9 
1 INTRODUCTION ......................................................................................... 15 
1.1 Background  ..................................................................................................................... 15 
1.2 Investigational Products  .................................................................................................. 15 
1.2.1  M207 (Zolmitriptan Microneedle System)  ............................................................. 15 
1.2.2  Zolmitriptan Nasal Spray  ........................................................................................ 15 
2 STUDY OBJECTIVES  ................................................................................. 16 
3 ETHICAL CONSIDERATIO NS ................................................................. 17 
3.1 Institutio nal Review  ........................................................................................................ 17 
3.2 Informed Consent  ............................................................................................................ 17 
4 INVESTIGATIONAL PLAN  ....................................................................... 18 
4.1 Overall Stud y Design  ...................................................................................................... 18 
4.2 Endpoints  ......................................................................................................................... 18 
4.3 Safety Considerations  ...................................................................................................... 19 
4.4 Study Po pulation  ............................................................................................................. 19 
4.4.1  Inclusion Criteria: .................................................................................................... 19 
4.4.2  Exclusion Criteria:  ................................................................................................... 19 
4.5 Early Termination  ........................................................................................................... 21 
5 STUDY TREATMENTS  ............................................................................... 22 
5.1 Study Drug Treatments  ................................................................................................... 22 
5.2 Study Treatment Assignment and Schedule .................................................................... 22 
5.3 Study Treatment Accountability Procedures ................................................................... 22 
5.4 Prior and Concomitant Medications Allowed and Prohibited During the Study  ............ 23 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 6 of 69 
 6 STUDY VISIT SCHEDULE  AND GENERAL CONSIDE RATIONS  ..... 24 
6.1 Screening  ......................................................................................................................... 24 
6.1.1  Screening Visit (U p to 30 days prior to the Admission/Baseline Visit)  ................. 24 
6.2 Admission/Baseline Visit (Day Before the first Dose)  ................................................... 25 
6.3 Study Dosing Days  .......................................................................................................... 26 
6.3.1  Dosing Visit (all Periods) – All Treatments  ............................................................ 26 
[IP_ADDRESS]  Pre-Dose -  Before treatment Administration on the Day of Dos ing ................ 26 
[IP_ADDRESS]  Treatment Administration (time 0 is application of second patch)  .................. 27 
[IP_ADDRESS]  2 Minutes after Treatment Administration  ....................................................... 27 
[IP_ADDRESS]  5 Minutes after Treatment Administration  ....................................................... 27 
[IP_ADDRESS]  10 Minutes after Treatment Administration  ..................................................... 27 
[IP_ADDRESS]  15 Minutes after Treatment Administration  ..................................................... 27 
[IP_ADDRESS]  20 Minutes after Treatment Administration  ..................................................... 27 
[IP_ADDRESS]  30 Minutes after Treatment Administration  ..................................................... 27 
[IP_ADDRESS]  45 Minutes after Treatment Administration  ..................................................... 28 
[IP_ADDRESS]  60 Minutes after Treatment Administration  ..................................................... 28 
[IP_ADDRESS]  90 Minutes after Treatment Administration  ..................................................... 28 
[IP_ADDRESS]  Two Hours after Treatment Administration  ..................................................... 28 
[IP_ADDRESS]  Four Hours after Treatment Administration  ..................................................... 28 
[IP_ADDRESS]  Eight Hours after Treatment Administration  .................................................... 28 
[IP_ADDRESS]  Twelve Hours after Treatment Administration  ................................................ 28 
[IP_ADDRESS]  Twenty Four Hours after Treatment Administration  ........................................ 29 
[IP_ADDRESS]  Zolmitriptan PK Sample Handling  ................................................................... 29 
6.4 End of Study Visit/or Early Termination  ........................................................................ [ADDRESS_308102] Study Phone Call -  Follow -up on Adverse Events  .................................................. 29 
6.6 Early Termination  ........................................................................................................... 29 
7 STUDY PROCEDURES  ............................................................................... 30 
7.1 General Confinement Restrictions  .................................................................................. 30 
7.2 Collection, Processing and Assay of Samples  ................................................................ 30 
7.3 Assessment Details  .......................................................................................................... 30 
7.3.1  Clinical Laboratory Tests  ........................................................................................ 30 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 7 of 69 
 7.3.2  Vital Signs  ............................................................................................................... 31 
7.3.3  Electrocardiog rams  .................................................................................................. 31 
7.3.4  Investigator Visual Skin Assessments of the Application Sites  .............................. 31 
[IP_ADDRESS]  Erythema  ........................................................................................................... 31 
[IP_ADDRESS]  Edema  ............................................................................................................... 32 
[IP_ADDRESS]  Bruising  ............................................................................................................ 32 
[IP_ADDRESS]  Bleeding  ............................................................................................................ [ADDRESS_308103] Information .......................................................................... 38 
8.4.2  Follow up of Adverse Events  .................................................................................. 39 
9 DATA MANAGEMENT  ............................................................................... 40 
9.1 Data Collection  ................................................................................................................ 40 
9.2 Database Management and Quality Control  ................................................................ ... 40 
10 STATISTICAL METHODS AND DATA ANALYSIS  .............................. 41 
10.1  Sample Size Considerations  ............................................................................................ 41 
10.2  Demographics and Baseline Characteristics  ................................................................... 41 
10.3  Analysis Population and Handling of Drop- Outs  ........................................................... 41 
10.4  Zolmitriptan Pharmacokinetics  ....................................................................................... 41 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 8 of 69 
 10.5  Analyses of Safety Data  .................................................................................................. 42 
10.6  Analyses of Residual Drug .............................................................................................. 42 
11 ADMINISTRATIVE PROCE DURES  ......................................................... 43 
11.1  Chang es to the Protocol ................................................................................................... 43 
11.2  Investigator Reporting Responsibilities to the Independent Ethics Committee and Other 
Agencies  43 
11.3  Withdrawal and Study Termination  ................................................................................ 43 
11.4  Monitoring ....................................................................................................................... 43 
11.5  Retention of Documents  .................................................................................................. 44 
11.6  Publicaton Policy ............................................................................................................. 44 
11.7  Auditing Procedures  ........................................................................................................ 44 
12 REFERENCES  .............................................................................................. 45 
13 SCHEDULE OF ASSESSME NTS  ............................................................... 46 
APPEN DIX 1: M207 PATCH ADMINISTRATION  ............................................................ 48 
APPEN DIX 2: ZOLMITRIPTAN  PK SAM PLE HANDL ING  .......................................... 57 
APPENDIX 3:  HANDLING  AND PROCESSING OF USED PATCHES AND SKIN 
SWABS ........................................................................................................... 58 
APPENDIX 4:  SHIPPI[INVESTIGATOR_253302]  ............................................................................................ 63 
APPENDIX  5: DECLARATION OF HELSINKI ................................................................ [ADDRESS_308104] C rossover S tudy to C ompare 
the P harmacokinetics, S afety, and Tolerability of Three Different 
Formulations of M207 3.8 mg ( Administered as two 1.9 mg 
patches) on the Upper arm  for 30 M inutes with Intranasal 
Zolmitriptan 2.5  mg in H ealthy Volunteers  
SPONSOR  Zosano Pharma  
CLINICAL PHASE  Phase 1 – Single Center  
INDICATION  Acute Treatment of Migraine  
OBJECTIVES  1. To compare the pharmacokinetics, safety and tolerability of 
M207 3.8 mg Treatment A  to M207 3.8 mg  Treatment B  to 
M207 3.8 mg Treatment C , worn for 30 minutes on the 
upper arm  
2. To compare the pharmacokinetics, safety and tolerability of three formulations of 
M207 3.8 mg to intranasal zolmitriptan 
2.5 mg  
TREATMENTS  • Treatment A: M207 3.8 mg administered as two 1.9 mg patches , 30 min wear time (upper arm application)  – made 
on a “Sled” coater and packaged in foil pouches  
• Treatment B: M207 3.8 mg administered as two 1.9 mg 
patches , 30 min wear time ( upper arm application)   - made 
on a “MACAP” coater and packaged in foil cups  
• Treatment C :  M207 3.8 mg administered as two 1.9 mg 
patches , 30 wear time (upper arm  application)  – made on a 
“MiniMac” coater and packaged in foi l cups  
• Treatment D: Intranasal zolmitriptan 2.5mg  
BLINDING  Open -label  
RANDOMIZATION  Randomized to the sequence of treatments  
STUDY POPULATION  Healthy volunteers (females and males) ; No more than 10% of the 
24 subjects randomized will be of black or  African A merican race  
  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 10 of 69 
 NUMBER OF  
SUBJECTS  24 (12 females; 12 males)  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 11 of 69 
 ELIGIBILITY  Inclusion Criteria  
1. Women or men 18 to 50 years of age  (inclusive)  
2. Good general health with no clinically significant  
abnormalities as determined by [CONTACT_9870], physical 
examination, CBC, blood chemistry, urinalysis, and ECG.  
3. Negative urine drug and alcohol screens and negative serum 
pregnancy tests (for female subjects) at screening  and 
admission/ baseline visit.  
4. Consent of female subjects to use a medically effective method of contraception throughout the entire study period and for [ADDRESS_308105] include abstinence, use of diaphragm and spermicide, intrauterine device (IUD),  rings,  condom 
and vaginal spermicide, hormonal contraceptives (subjects must be stable on hormonal contraceptives for at least 3 months  prior to screening ), surgical sterilization  
(hysterectomy, bilateral tubal ligation, hysteroscopic 
sterilization)  and post -menopausal ( ≥ 2 years of 
amenorrhea).   
5. Ability to read, understand, and provide written informed consent that they understand the purpose of the study and procedures required for t he study before enrolling in the 
study, and willingness to comply with all study procedures and restrictions.  
Exclusion Criteria  
1. Evidence of significant history of hepatic, reproductive, gastrointestinal, renal, bleeding, or hematological disorders 
including coagulation, pulmonary, neurological, respi[INVESTIGATOR_696], 
endocrine, or cardiovascular system abnormalities (especially hypertension, peripheral vascular disease, coronary artery disease, transient ischemic attacks, or cardiac rhythm abnormalities ), psy chiatric disorders, acute 
infection, or other  conditions that would interfere with 
study participation or with the absorption, distribution, metabolism, or excretion of drugs.  
2. Presence of t hree or more  of the following CAD  risk factors 
for cardiovascular diseas e:  
A. Current tobacco use  (subjects who have 
smoked within 30 days of screening)   
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 12 of 69 
 B. Hypertension (systolic BP > 140 or diastolic 
BP > 90) or receiving anti -hypertensive 
medication for treatment of hypertension  
C. Hyperlipi[INVESTIGATOR_035] – LDL > 159 mg/dL and/or 
HDL <  40 mg/dL (or on prescribed anti -
cholesterol treatment)  
D. Family history of premature coronary artery 
disease (CAD) (< [ADDRESS_308106]-degree relatives or <  [ADDRESS_308107] degree relatives)  
E. Diabetes mellitus  
3. Any contraindicatio n to zolmitriptan  administration 
including:  
• History of coronary artery disease or coronary 
vasospasm  
• Symptomatic Wolf -Parkinson- White syndrome or 
other cardiac accessory conduction pathway disorders  
• History of stroke, transient ischemic attack, or 
hemipleg ic or basilar migraine  
• Peripheral Vascular Disease  
• Ischemic bowel disease  
• Hypertension (greater than or equal to 140/90 
mmHg  at either the screening or admission/ baseline 
visit  
• Any history of hepatic impairment defined as ALT > 150 U/L, AST > 130 U/L or bilirubin > [ADDRESS_308108] dose  
7. Use of prescription and over the counter medications within 
one week of dosing other than the following:  
• Hormone Replacement Therapy (HRT)  
• Birth control pi[INVESTIGATOR_3353], patches, IUD,  rings,  injections, or 
implants (all hormonal contraceptives) are allowed 
provided the dose has been stable for at least three months  prior to screening and may be continued 
throughout the study  
• Proton Pump Inhibitors (PP Is) 
• Antihistamines  
• Intermittently used NSAIDS  
• Acetaminophen  if medically necessary  (not more 
than 1000 mg /day)  
• Exceptions may be allowed on a case by [CONTACT_413]  
8. Subject has a known allergy or sensitivity to zolmitriptan or 
its derivatives or formulations  
9. Subject has a k nown allergy or sensitivity to tapes  or 
adhesives  
10. Use of any other investigational compound within 30 days  
of planned study drug dosing  
11. Current use or history  of drug and/or alcohol abuse  within 6 
months of screening and deemed to be clinically significant 
by [CONTACT_093]  
12. History of nasal pathology (e.g., polyps) or abnormal nasal 
exam  deemed to be clinically significant by [CONTACT_093]  
13. Body Mass Index (BMI)  lower than 18 kg/m2  or greater  
than 35 kg/m2 
14. If, in the opi[INVESTIGATOR_871], the subject is not suitable for the study  
15. Any positive urine drug screen  result or alcohol  test 
16. Subject  currently smokes or is a nicotine a user  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 14 of 69 
 CENTERS  Single center  
STUDY DURATION  Screening  (up to 30 days prior to dosing ); in-clinic duration of 
study participation for  each subject is approximately 2 week s total 
(includes  4 treatment periods) , and the E nd of S tudy (or Early 
Termination) visit occurs on the day of discharge   
PROCEDURES & 
ASSESSMENTS  All procedures are performed relative to Time 0 ( M207 
application ), the time of second patch application.   
• Phys ical examination ( Screening,  [ADDRESS_308109] drug 
administration  and E nd of S tudy/or Early T ermination visit)  
• Clinical laboratory tests (Screening , and E nd of S tudy/or 
Early T ermination  visit)  
• Collection of  blood samples (pre -dose, 2, 5, 10, 15, 20, 30, 
45, 60, [ADDRESS_308110] -dose) 
for pharmacokinetics determination  
• Vital signs ( Screening, pre -dose and [ADDRESS_308111] -dose and End of study /or E arly T ermination 
visit)  
• 12-lead ECGs ( Screening, pre -dose, [ADDRESS_308112]-dose, 
and E nd of S tudy/ or Early Termination visit)  
• Investigator visual skin assessment of the M207 application site at  pre-dose, [ADDRESS_308113] -dose, and 
End of S tudy/or E arly termination visit  
• Residual zolmitripan  swabbing on the skin at [ADDRESS_308114] -
dose 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 15 of 69 
 1 INTRODUCTION 
1.1 Background  
Zosano Pharma  has developed a zolmitriptan microneedle system (M207) as a potential therapy 
for the acute treatment of migraine.   To date, three  trials have been completed, two  
pharmacokinetic studies  in healthy volunteers, and a single treatment efficacy and sa fety study in 
subjects with migraine.  A long -term safety study is ongoing.   In all  studies, the M207 system 
(“patch”) was applied to the upper arm for [ADDRESS_308115] not changed over the course of development.  This 
study is designed to compare pharmacokinetics seen after administration of  patches (treatments 
A, B, and C) made from the three different types of equipment. 
1.2 Investigational Products  
1.2.1 M207 (Zolmitriptan Microneedle System ) 
The Zosano M207 (Zolmitriptan Microneedle System ) is a novel drug delivery technology which 
consists of a disposable titanium microneedle patch centered on an adhesive backing that are dry -
coated with the drug product formulation, and a reusable handheld applicator that ens ures that 
the patch is applied with a defined application speed and energy to the site of administration.  M207 systems consist of zolmitriptan coated titanium array with an adhesive backing that is 
applied using proprietary patch applicators.  Descriptions of the 1.[ADDRESS_308116] (Zomig ® Nasal Spray) and will be 
purchased for use in this study .  The dose used in this study will be 2.5 mg/0.[ADDRESS_308117] blow s his/her nose, t his dose should be administered to either the right or left nostril with 
the subject’s head tilted slightly backward.  
M207 1.9 mg Patch  
The M207 1.9 mg  consists of a 3 cm
2  titanium array of microneedles  that are nominally 340 µm 
in length coated with 1.9 mg of zolmitripan .  The array is applied to the center of a 5 cm2 tan 
adhesive patch.  The patch is attached to the interior  of a white to off -white polycarbonate ring 
co-molded with a desiccant , packaged in a  foil pouch (treatmen t A) or  cup (treatment B and C) . 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 16 of 69 
 2 STUDY OBJECTIVES  
The study objectives are as follows:  
To compare the pharmacokinetics, safety and tolerability of M207 3.[ADDRESS_308118] be conducted in compliance with the protocol; the U.S. Code of Federal 
Regulations (CFR); the International Conference on Harmonisation (ICH -R) Good Clinical 
Practice (GCP) Guidelines; the Declaration of Helsinki (see Appendix 5); and all applicable federal, state and local laws, r ules and regulations relating to the conduct of the study.  
All members of the Investigator’s staff have signed confidentiality agreements. By [CONTACT_12570], the Investigator and investigational staff will regard all information provided by [CONTACT_214106].  
The Investigator must guarantee the privacy of the subjects taking part in the study. Subjects will 
be identified throughout documentation and evaluation by a unique subject study number. Throughout the study, a subject’s source data will only be linked to the Sponsor’s clinical study database or documentation via a unique identification number. If subject name [CONTACT_214113], it must be redacted before the copy  of the documents is supplied to the Sponsor. 
Any information concerning the subjects (clinical notes, identification numbers, etc.) must be kept on file by [CONTACT_214107], IRB, or regulatory author ities for the purposes of trial monitoring, auditing or official inspections. As 
required, in the case of an event where medical expenses are the responsibility of the Sponsor, personal information, i.e., full name, social security details, etc., may be re leased to the Sponsor. 
Appropriate precautions will be taken to maintain confidentiality of medical records and personal information in strictest confidence and in accordance with local data protection laws. 
3.1 Institutional Review  
Prior to the initiation of clinical studies, the protocol, the Informed Consent Form (ICF), 
amendments to the protocol and ICF, advertisements and any other information for subjects will be reviewed and approved by [CONTACT_253315] ( IEC) of 
the participating study center in accordance with the CFR, the ICH -R and institutional EC 
policies.  All protocol amendments (See Section  11.1) and changes to the consent form occurring 
during the study must also be IRB/ IEC approved.  
3.2 Informed Consent  
Prior to study inception, each study participant or the legally authorized representative will be required to read, sign, and date an IRB/IEC approved ICF explaining the nature, purpose, 
possible risks and benefits of the study, and the duration of an individual’s participation in the study.  The clinical site personnel who conducted the informed consent discussion must also sign and date the consent form.  Each subject or legally authorized representative will be given a copy of the ICF.  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
[ADDRESS_308119] will 
receive each of the four study treatmen ts once , followed by [INVESTIGATOR_2993]- clinic monitoring and extensive 
blood sample collection for pharmacokinetic analysis. 
Dosing will occur approximately 48 hours apart  from the time of patch application , until 
complet ion of dosing in randomized order per the treatment sequence schedule.  Plasma samples  
from the dosing days will be sent to the analytical laboratory for analysis  and tolerability for each 
of the dose levels will be  summarized . 
After completion of the  four dosi ng days, subjects will be assessed one final time and dismissed 
from the study.  
4.2 Endpoints  
The endpoints of the study are:  
Safety and Tolerability  
• Incidence of adverse events  
• Change in physical exam findings from pre -dose to [ADDRESS_308120] -dose  
• Change s in vital sig ns from pre -dose to [ADDRESS_308121]-dose  
• Change s in ECG parameters from pre -dose to [ADDRESS_308122] -dose  
• Scores from the  investigator visual skin assessment for erythema, edema, bruising and 
bleeding  at the patch application site s from pre -dose to [ADDRESS_308123] -dose 
Pharmacokinetics  
• Cmax - maximum observed plasma concentrations  
• Tmax - time to maximum concentration  
• AUC 0-last - the area under the plasma concentration time profile from hour [ADDRESS_308124] 
detectable concentration at time t.  
• AUC 0-30min - the area under the plasma concentration time profile from minute 0 to 
minute 30. 
• AUC 0-60min - the area under the plasma concent ration time profile from minute 0 to 
minute 60. 
• AUC 0-120min  - the area under the plasma concentration time profile from minute 0 to 
minute 120. 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 19 of 69 
 • k - apparent elimination rate constant will be estimated by [CONTACT_253316]-transformed plasma concentrations during the terminal log -linear decline phase.  
• t1/2 - apparent half -life (t 1/2) values will be calculated as 0.693/k.  
• AUC 0-inf - the AUC value extrapolated to infinity will be calculated as the sum of AUC t, 
and the area extrapolated to infini ty, calculated by [CONTACT_253317] t (C t) divided 
by k.  
• Frel -  bioavailability relative to each treatment assignment  
4.3 Safety Considerations  
M207 consisting of two  patches  each  1.9 mg (3.8 mg), 30 minute  upper arm application, has 
been studied in healthy volunteers (in clinic) and subjects with migraine (outpatient).  This 
regimen has been generally well -tolerated, with adverse events observed (dizziness and chest 
tightness) of those typi[INVESTIGATOR_253303].  Adverse events reported were almost always 
within the first few minutes after patch application.   
4.[ADDRESS_308125]  of 24 healthy volunteers  (12 women and 12 men ) 18 to 
50 years of age  in general good he alth. 
4.4.1 Inclusion Criteria:  
1. Women or men 18 to 50 years of age  (inclusive)  
2. Good general health with no clinically significant abnormalities as determined by [CONTACT_177964], physical examination, CBC, blood chemistry , urinalysis, and ECG. 
3. Negative urine drug and alcohol screens and negative serum pregnancy tests (for female 
subjects) at screening  and admission/ baseline visit. 
4. Consent of female subjects to use a medically effective method of contraception throughout the entire study period and for [ADDRESS_308126] include abstinence, use of 
diaphragm and spermicide, intrauterine device (IUD), rings, condom and vaginal spermicide, hormonal contraceptives (subje cts must be stable on hormonal contraceptives for at least 3 
months  prior to screening ), surgical sterilization  (hysterectomy, bilateral tubal ligation, 
hysteroscopic sterilization) and post -menopausal ( ≥ 2 years of amenorrhea).   
5. Ability to read, understa nd, and provide written informed consent that they understand the 
purpose of the study and procedures required for the study before enrolling in the study, and willingness to comply with all study procedures and restrictions.  
4.4.2 Exclusion Criteria:  
1. Evidence o f significant history of hepatic, reproductive, gastrointestinal, renal, bleeding, or 
hematological disorders including coagulation, pulmonary, neurological, respi[INVESTIGATOR_696], endocrine, or cardiovascular system abnormalities (especially hypertension, periphera l 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 20 of 69 
 vascular disease, coronary artery disease, transient ischemic attacks, or cardiac rhythm 
abnormalities), psychiatric disorders, acute infection, or other  conditions that would interfere 
with study participation or with the absorption, distribution, metabolism, or excretion of drugs.  
2. Presence of three or more of the following CAD risk factors for cardiovascular disease:  
A. Current tobacco use  (subjects who have smoked within 30 days of screening)  
B. Hypertension (systolic BP > 140 or diastolic BP > 90) or receiving anti -hypertensive 
medication for treatment of hypertension  
C. Hyperlipi[INVESTIGATOR_035] – LDL > 159 mg/dL and/or HDL <  40 mg/dL (or on prescribed anti -
cholesterol treatment)  
D. Family history of premature coronary artery disease (CAD) (< [ADDRESS_308127]-degree relatives or <  [ADDRESS_308128] degree relatives)  
E. Diabetes mellitus  
3. Any contraindication to zolmitriptan  administration including:  
• History of coronary artery disease or coronary vasospasm  
• Symptomatic  Wolf -Parkinson- White syndrome or other cardiac accessory conduction 
pathway disorders  
• History of stroke, transient ischemic attack, or hemiplegic or basilar migraine  
• Peripheral Vascular Disease  
• Ischemic bowel  disease  
• Hypertension (greater than or equal to 140/90 mmHg at either the screening or 
admission/ baseline visit  
• Any history of hepatic impairment defined as ALT > 150 U/L, AST > 130 U/L or 
bilirubin > [ADDRESS_308129] dose  
7. Use of prescription and over the counter medications  within one week of dosing other than 
the following:  
• Hormone Replacement  Therapy (HRT)  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 21 of 69 
 • Birth control  pi[INVESTIGATOR_3353], patches, IUD,  rings, injections, or implants (all hormonal 
contraceptives) are allowed provided the dose has been stable for at least three months  
prior to screening and may be continued throughout the study  
• Proton Pump Inhibitors (PPIs)  
• Antihistamines  
• Intermittently  used NSAI DS 
• Acetaminophen  if medically necessary (not more than 1000 m g/day)  
• Exceptions may be allowed on a case by [CONTACT_413]  
8. Subject  has a known allergy or sensitivity to zolmitriptan or its derivatives or formulations  
9. Subject has a k nown allergy or sensitivity to tapes  or adhesives  
10. Use of any other investigational compound within 30 days  of planned study drug dosing  
11. Current use or history of  drug and/or alcohol abuse within 6 months of screeningand  deemed 
to be clinically significant by [CONTACT_093]  
12. Histor y of nasal pathology (e.g., polyps) or abnormal nasal exam  deemed to be clinically 
significant by [CONTACT_093]  
13. Body Mass Index (BMI) lower than 18 kg/m2 or greater than 35 kg/m2 
14. If, in the opi[INVESTIGATOR_871], the subject is not suitable for the study  
15. Any positive urine drug screen  result or alcohol test  
16. Subject  currently smokes or is a nicotine a user  
4.[ADDRESS_308130] can be withdrawn for any of the following reasons: the 
Principal Investigator [INVESTIGATOR_253304] , a subject is non- compliant with the protocol, a subject has a serious reaction to the 
treatment, or the study is stopped by [CONTACT_11390], US Food and Drug 
Administration (FDA), or Zosano Pharma.  
In order to complete all treatments for each dose, additional subjects may be enrolled to account 
for subjects who withdraw or are discontinued from the study.  If a subject does not complete all planned treatments, the reason and date of withdrawal from the study must be recorded in the 
CRF.  Zosano Pharma shoul d be notified immediately if a subject withdraws prematurely from 
the study.  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 22 of 69 
 5 STUDY TREATMENTS  
5.1 Study Drug Treatments  
The treatments are:  
• Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 min wear time (upper 
arm application)  - made on a “Sled” coater and packaged in foil pouches  
• Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 min wear time (upper 
arm application)  - made on a “MACAP” coater and packaged in foil cups  
• Treatment C : M207 3.8 mg administered as two 1.9 mg patches 30 min wear time (upper 
arm application)  - made on a “MiniMac” coater and packaged in foil  cups  
• Treatment D: zolmitriptan  nasal 2.5 mg /0.1 ml  (single dose)  
Depending  on the treatment assignment, two M207 patches will be applied to the upper arm by 
[CONTACT_3553] a handheld reusable applicator with an application energy of 0.26  Joules .  Used p atches 
will be removed  30 minutes after application  of the second patch .  The  patches  will be collected 
and frozen in storage until shipped for analysis of remaining  drug.  
The applicator  systems  and unused patches  should be stored at room temperature, not to exceed 
15-30°C ( 59-86°F).  Unused patches should not be refrigerated or frozen.  
5.2 Study Treatment Assignment and Schedule  
The 24 subjects are planned to recei ve each of the four treatments (A, B, C , D) [ADDRESS_308131]’s investigational treatment.  Reasons for departure from the expected dispensing and dosing regimen will also be documented.  All left over used and unused study patches should be retained for drug accountability auditing to be performed by [CONTACT_253318].  At the conclusion of the study, the study drug accountability records must 
accurately reflect the receipt and final disposition of all study drug shipped to the site.  Destruction or return of remaining used and unused drug supplies by [CONTACT_253319] . 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 23 of 69 
 5.4 Prior and Concomitant Medications Allowed  and P rohibited  During the Study  
Subjects will be asked to refrain from taking either prescription or OTC (inclusive of herbal) 
medications within one week prior to dosing  until the completion of the study, except for those 
discussed in this section.  All concomitant medications taken during the study will be recorded on the concomitant medications case report form (CRF) wi th indication for use, totally daily 
dosage, and dates of drug administration. 
Allowed prescription and over the counter medications: 
• Hormone  Replacement Therapy (HRT)  
• Birth  control pi[INVESTIGATOR_3353], patches, IUD,  rings,  injections, or implants (all ho rmonal 
contraceptives) are allowed provided the dose has been stable for at least three months  
prior to screening and may be continued throughout the study  
• Proton Pump Inhibitors (PPIs)  
• Intermittently  used NSAIDS  
• Acetaminophen  may be administered if medically necessary (not more than  1000mg /day)  
• Antihistamines  
All other concomitant medications will be prohibited, except as specifically exempted by [CONTACT_253320] a case -by-case basis.  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
[ADDRESS_308132] be a minimum of 48 hours  (from time 0 = application of 
patches)  until  the next dose .  Subjects will be required to stay in the clinic for the entire duration 
of the study  (unless medically necessary to leave the clinic as instructed by [CONTACT_1961]  [INVESTIGATOR_1238]/or  for non- medical ly related reasons considered on a case by [CONTACT_413] ). 
The PK samples should be drawn as close as possible to the specified time. When multiple 
procedures are scheduled for the same time point, PK samples will be taken at the protocol assigned time point within plus or minus [ADDRESS_308133] hour and within plus or minus 5 minutes of the specified time points aft er one hour.  The other 
measurements (i.e., vital signs, ECG, skin assessments) will be taken before or after the protocol -
specified time point within an interval of plus or minus [ADDRESS_308134] of four  sequential treatments within the 
study.  The screening procedures include:  
6.1.1 Screening Visit  (Up to 30  days prior to the Admission/Baseline Visit ) 
Subjects who are considered to be good candidates for the study will be seen in the clinic and have the following procedures performed:  
• Obtain informed consent  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 25 of 69 
 • Obtain a m edical history  and demographics  
• Record concomitant  medications  
• Perform a p hysical exam ination  
• Measure Vital signs  (inclusive of temperature)  
• Measure height  
• Measure body weight  and calculate BMI  
• Confirm eligibility  
• Collect blood and urine  samples for clinical laboratory tests  
• Perform serum pregn ancy  test ( for all  females ) 
• Collect blood for s erology  (HIV, Hepatitis B, Hepatitis C)  
• Perform urine drug and  alcohol  testing  
• Record a 12- lead ECG  
Medical history, physical examination, ECG and laboratory findings are to be reviewed, and 
eligibility determined .  The sponsor must approve any exception to the inclusion or exclusion 
criteria before planned admission for dosing.  
A subject number will be assigned when the subject signs the informed consent.  Only subject number, initials and date of birth will ide ntify subjects to the Sponsor.  In the event that a subject 
who has signed the informed consent but did not receive a dose of study medication experiences 
an SAE, the following information will be captured: demographic data (initials, age, and race), all other Screening assessments that have been completed, AE(s), and concomitant 
medication(s).  
6.2 Admission /Baseline  Visit  (Day B efore the first  Dose) 
If subjects continue to meet all entry criteria  on the day prior t o the first  dosing, the subject will 
stay in  the clinic overnight  and through the final discharge.  The following procedures will be 
performed th e day prior to  the first  dosing  only : 
• Record concomitant medications  
• Perform urin e drug and alcohol testing  
• Serum  pregnancy test ( all women ) 
• Collect  vital signs (inclusive of  temperature)  
• Confirm eligibility  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
[ADDRESS_308135] 2 hours 
after dosing.  Water is allowed ad libitum, as well as tea and coffee in moderate amounts .  The 
following mo rning (between 0630 and 0930) , subjects  will receive that day’s scheduled 
treatment (A, B, C  or D ).  Breakfast should be withheld until at least two hours post  patch 
application .   
No lotions, ointments, or pow ders may be  applied  to the upper arm where  M207 will be applied 
for [ADDRESS_308136] ying M207.  
All AEs, including any skin irritations and sensations as well as concomitant medication usage 
will be documented.  
When multiple assessments are  required at the same time point, they will be conducted in the 
order  as specified in the footnotes of the S chedule of Assessment .  All procedures should be 
performed relative to “Time 0” ( M207 application) when a time is listed.  
6.3.1 Dosing  Visit  (all P eriods)  – All Treatments  
The following procedures will be performed on each of the four  dosing days.  The actual 
procedures will be identical at each of the dosing days, only the study drug administered on each of the treatment days will vary.  
[IP_ADDRESS] Pre-Dose -  Before t reatment Administration  on the D ay of  Dosing  
• Record concomitant medications  
• Confirm eligibility  
• Measure v ital signs  
• Record a 12 -Lead ECG  
• Investigator visual skin assessment  
•  Nasal assessment  (visual inspection)  for treatment D assignment only  
• Determine that subject  is stable and in good health and appropriate for dosing 
• Collect blood for a PK sample within 15 minutes  prior to administering study drug  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 27 of 69 
 [IP_ADDRESS] Treatment Administration (t ime 0 is application of second patch ) 
• Apply patches  or administer  intranasal zolmitriptan (see Appendix [ADDRESS_308137] ration ) 
• Begin r ecord ing all AEs, whether observed by [CONTACT_1697], reported by [CONTACT_423], 
observed in laboratory findings, or discovered by [CONTACT_253321], on the AE CRF through 
the End of S tudy ( or Early Termination ) final visit.   All adverse events must be followed 
to resolution. 
[IP_ADDRESS] 2 Minutes after T reatment A dministration  
• Collect blood for  a PK sample  
• Record concomitant medications  
[IP_ADDRESS] 5 Minutes after T reatment A dministration  
• Collect blood for  a PK sample  
• Record concomitant medications   
[IP_ADDRESS] 10 M inutes after T reatment A dministration  
• Collect blood for a PK sample  
• Measure vital signs  
• Record concomitant medications   
[IP_ADDRESS] 15 M inutes after T reatment A dministration  
• Collect blood for a PK sample  
• Record a 12 -Lead ECG  
• Record concomitant medications   
[IP_ADDRESS] 20 Minutes after Treatment Administration  
• Collect blood for a PK Sample  
• Record concomitant medications   
[IP_ADDRESS] 30 M inutes after T reatment A dministration  
• Collect blood for  a PK sample  following removal of the second patch  
• Record concomitant medications and adverse events  
• Remove patch es and perform the following procedures in the order listed below : 
• Investigator visual skin assessment of the  patch  application sites  within one minute of 
removing both patches and prior to swabbing   
• Retain and package patch es for freezing. Refer to full instructions in Appendix 3.  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 28 of 69 
 • Application site swabbing. Refer to full instructions in Appendix 3.  
[IP_ADDRESS] 45 M inutes after T reatment A dministration  
• Collect blood for a PK sample  
• Record concomitant medications  
[IP_ADDRESS] 60 M inutes after T reatment A dministration  
• Collect blood for  a PK sample  
• Measure vital signs  
• Record concomitant medications and adverse events  
[IP_ADDRESS] 90 M inute s after T reatment A dministration  
• Collect blood for a PK sample  
• Record concomitant medications   
[IP_ADDRESS] Two H ours after T reatment A dministration  
• Collect blood for a PK sample  
• Measure vital signs  
• Record concomitant medications   
[IP_ADDRESS] Four H ours after T reatment A dministration  
• Collect blood for a PK sample  
• Measure v ital s igns 
• Record concomitant medications   
[IP_ADDRESS] Eight H ours after T reatment A dministration  
• Collect blood for a PK Sample  
• Record concomitant medications   
• Investigator visual skin assessment of the application sites  
• Perform a physical examination  
[IP_ADDRESS] Twelve H ours after T reatment A dministration  
• Collect blood for a PK Sample  
• Measure v ital s igns 
• Record a 12 -Lead ECG  
• Determine if subject is stable for the next dosing period  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 29 of 69 
 • Record concomitant medications  and adverse ev ents 
[IP_ADDRESS] Twenty F our H ours after T reatment A dministration  
• Collect blood for a PK Sample  
• Record concomitant medications and adverse events  
• Investigator visual skin assessment of the application sites  
[IP_ADDRESS] Zolmitriptan  PK S ample H andling  
Details related to zolmitriptan  PK sample collection and shipment is provided in Appendix 2. 
6.4 End of Study Visit /or Early Termination  
• Within [ADDRESS_308138] dosing 
day, subjects w ill complete  an End of Study V isit.  At that time, the following 
assessments will be performed:  
• Record all AEs, whether observed by [CONTACT_1697], reported by [CONTACT_423], observed in 
laboratory findings, or discovered by [CONTACT_11174], on the AE CRF through the end of study final visit.  
• Record a 12 -Lead ECG  
• Record any new concomitant medications  and adverse events  
• Measure vital signs  (inclusive of temperature)  
• Perform a physical examination  
• Measure body weight  
• Investigator visual skin assessment of the application sites  
• Collect blood and urine for laboratory tests and  serum  pregnancy test  (for all females ) 
• Discharge subject from the study  
6.[ADDRESS_308139] study phone call is required if any adverse events are ongoing at the time 
of discharge . 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 30 of 69 
 7 STUDY PROCEDURES  
7.1 General Confinement Restrictions  
Subjects will be required to stay in the clinic for the entire duration of the study ( unless 
medically necessary to leave the clinic as instructed by [CONTACT_253322]/or for non-
medically related reasons considered on a case by [CONTACT_413]).  
7.2 Collection, Processing and Assay of Samples  
Each of the plasma samples collected for pharmacokinetic analysis will be separated into two 
containers.  One of the samples wil l be sent to the analytical laboratory for analysis and one 
sample will be maintained at the investigative site  until authorization is received form the 
sponsor to send the remaining samples to the bioanalytical lab.  The plasma  sample retained at 
the site  may be used for further analysis (additional metabolites, etc.) at some future timepoint.  
Subjects who complete all four  treatments will have a blood draw volume of approximately 
279 mL for the entir e duration of the study (See Table below ). 
Blood Volume Requirements  (mL)  
Purpose  Expected Number  Sample Amount  
(in mL)  Total Amount  
(in mL)  
Clinical laboratory tests  
(Chemistry , Serology, 
and Serum Pregnancy ) 2 12 24.0 
Serum Pregnancy 
(Admission/baseline  and 
end of study ) 2 3.5 7.0 
Hematology  2 4.0 8.0 
PK 60 (15 samples per period x 
4 periods)  4.[ADDRESS_308140] clinical laboratory tests  (serum pregnancy for all women, chemistry , hematology, and 
urinalysis ) will be performed at Screening  and End of  Study ( or Early T ermination ) visit.  A 
serum pregnancy test  will also be completed  for all women  at the  Admission /baseline  visit. 
Screening  serological tests for HIV, Hepatitis B and Hepatitis C  will be performed . 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 31 of 69 
 Hematology  will include the following: Hematocrit, hemoglobin, red blood cell count, white 
blood cell count with differential, platelets, mean corpuscular volume, mean corpuscular 
hemoglobin, and mean corpuscular hemoglobin concentration.  
Blood chemistry  will include the following: Urea , glucose, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), alkaline phosphatase (AP), lactate dehydrogenase (LDH), sodium, phosphate, potassium, chloride, creatinine phosphokinase (CPK), globulin, cholesterol, creatinine, serum calcium, t otal bilirubin, triglyceride , cholesterol (HDL and LDL), gamma 
glutamyl transpeptidase (GGT) and uric acid.  
Urinalysis will include the following: bilirubin, blood, glucose, ketones, leuokocyte esterase, nitrite, pH, protein, specific gravity, and urobilinogen.  Microscopic examination will be conducted if protein, leukocyte esterase, nitrite and/or blood are detected.  
Urine drug  screen and alcohol   testing will be performed at screening and the A dmission /baseline  
visit.  Urine drug screen will test for amphetamine, barbituates, cocaine, cannabinoids, phencyclidine (PCP), opi[INVESTIGATOR_2438], and methamphetamines. 
Samples will be analyzed by a local laboratory.   After reviewing the laboratory reports and 
evaluating the results, the Inv estigator must review, sign/date the laboratory report.  
7.3.[ADDRESS_308141] been in the  seated  resting  position  for 2 minut es.  
Temperature will be taken at Screening , admission/baseline,  and at end of study  visit/ or early 
termination only.  
7.3.[ADDRESS_308142] 12- lead ECG  will be performed by a qualified individual at the site.  General 
morphology and interva ls [Heart rate, QRS, PR  interval , QRS, QT n, QTc f], of interest will be 
assessed with each tracing.  The principal or  sub- investigator must review the tracing  and assess 
it for any clinically significant abnormality.  Any clinically significant ECG  abnormality noted at 
the time of screening and/or pre -dose will be recorded in the appropriate source document and 
may result in the exclusion of the subject from the study.  
7.3.4 Investigator Visual Skin Assessments of the Application Site s 
Each M207 patch site (where a patch has been removed)  will be observed for the following skin 
assessments pre -dose and immediately after removal of the patch es from the subject’s skin ( and 
before swabbing ) at 30 min, 60 min, 8 hr , 24 hr  and at  the End of Study/or Early T ermination  
visit.  
[IP_ADDRESS] Erythema  
The erythema evaluations will be performed using the following scale:  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 32 of 69 
 • 0 = None  
• 1 = Mild redness  
• 2 = Moderate colored  redness  
• 3 = Beet colored redness  
[IP_ADDRESS] Edema  
The edema evaluations will be performed using the following scale:  
• 0 = None  
• 1 = Slight edema  
• 2 = Moderate edema  
• 3 = Severe edema  
[IP_ADDRESS] Bruising   
Bruising  assessments (visual rating) will be performed using the following scale:  
• 0 = None  
• 1 = ≤  25% application site has bruising spots  
• 2 = ≥  26 to ≤  50% application site has bruising spots  
• 3 = > 50% application site has bruising spots  
[IP_ADDRESS] Bleeding   
Bleeding will be assessed using the following scale: 
• 0 = None  
• 1 = Pi[INVESTIGATOR_253305] 
• 2 = Visible blood drop 
• 3 = Active bleeding 
7.3.[ADDRESS_308143] d on dry ice or  frozen at approximately -80°C (plus or minus 10° C) and kept 
frozen until s hipment to the bioanalytical lab .  Used patches may be assayed for residual 
zolmitriptan  if considered relevant after review of the pharmacokinetic res ults.  Instructions for  
removing  and storing the patches  are provided in Appendix 3.  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 33 of 69 
 7.3.6 Residual Drug on Skin after M207 Patch Removal  
At the time  patches are removed  and after the investigator skin assessment  (for all patch 
treatment groups) , the M207 patch skin sites will be swabbed to collect any residual drug that 
may be on the skin surface where a t ransdermal M207 patch has been applied.  The process 
consist s of using [ADDRESS_308144] patch application  until the end of the study  
(discharge from the clinic) .  A detailed discussion regarding the collection and reporting of 
adverse events is provided in Section  8.  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
[ADDRESS_308145], follow -up by [CONTACT_253323] a level acceptable to the Investigator, and Zosano Pharma concurs with that assessment.  
Reporting Period  
Collection of skin and systemic AEs will be initiated f rom the time of treatment  application  and 
will conclude when the end of study  procedures for the fouth treatment are completed (or Early 
Termination).  The Investigator will also report to the Sponsor all SAEs that come to his/her attention after the study  termination within [ADDRESS_308146], discovered by 
[CONTACT_253324], or detected through physical examination, laboratory or other means, 
will be collected and recorded on the Adverse Event CRF using the signs, symptoms or diagnosis associated with them and followed until resolution or, in the Investigator’s opi[INVESTIGATOR_1649], a stable condition is reached, or until the patient is lost to follow up. 
Medical conditions/diseases present before starting study treatment are only considered adverse 
events if they worsen after starting study treatment.  
In the event of a clinically impor tant AE, a blood sample may be collected as soon as possible 
after the occurrence of the event for drug assay or for additional laboratory tests.  The Investigator will ensure that the serum sample is properly labeled and stored.  The Investigator and othe r study personnel responsible for the care of the patient will institute any supplementary 
investigations of significant AEs based on the clinical judgment of the likely causative factor(s).  This may include seeking further opi[INVESTIGATOR_1101] a specialist in the field of the AE. 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 35 of 69 
 Any abnormal lab tests starting from the day of study patch application that are clinically 
significant, as determined by [CONTACT_737], should be reported as AEs if:  
• the test result is associated with accompanying symptoms;  
• the test re sult requires additional diagnostic testing or medical/surgical intervention; 
• the test result leads to a change in study dosing or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;  
• the test result is considered to be an AE by [CONTACT_253325], in the absence of any of the above conditions, does not constitute an AE.  Any abnormal test result that is determined to be an error does not require reporting as an AE. 
8.2 Documentation and Reporting of Adverse Events By [CONTACT_253326] (AEs) occurring after the application  of the first dose  through the End of 
study visit/or early termination , will be reported on the AE CRF pages.  Based on the medica l 
judgement of the investigator, all non- serious systemic and skin AEs will be followed until 
30 days after the final end of study visit.  All non- resolved, non- serious  systemic and skin AEs 
beyond such date will be recorded as ‘ongoing’ without further follow up.  
However, an AE form will not be filled out for subjects who sign the ICF but fail the entry criteria (Screening failures) during the Screening process and experience a non -serious AE.  
Application site reactions will be reported on a dedicated as sessment form for the visual skin 
assessment of the application site s.  The regular AE form does not have to be completed for such 
events unless the events are not covered by [CONTACT_253327].  However, all such events will be included in the 
analyses of adverse event incidence.  
Each AE, including skin AEs, is to be assessed to determine if it meets the criteria for an SAE.  
If an SAE occurs, expedited reporting will follow local and international regulations, as appropriate (See Section 8.4).  It should be noted that the form for collection of SAE information 
is not the same as the AE CRF.  Where the same data are collected, the forms must be completed in a consistent manner.  For example, the same AE term should be used on both forms.  Systemic and skin AEs should be reported using concise medical terminology on the CRF pages as  well as 
on the form for collection of SAE information. 
In addition to recording the signs, symptoms or diagnosis associated with them to describe the 
adverse event, the following will also be assessed and recorded:  
8.2.[ADDRESS_308147] the start date and time  of the event, and, if applicable, the end date  and time .  If the event 
is still ongoing  at the final or early termination visit or  after the end of follow -up, this should also 
be recorded.  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 36 of 69 
 8.2.2 Severity Ratings  
The Investigator will evaluate the severity of ea ch AE using the following definitions:  
• Mild -  event may be noticeable to patient; does not influence daily activities; usually does 
not require intervention. 
• Moderate -  event may be of sufficient severity to make patient uncomfortable; 
performance of daily  activities may be influenced; intervention may be needed. 
• Severe -  event may cause severe discomfort; usually interferes with daily activities; 
patient may not be able to continue in the study; treatment or other intervention usually 
needed.  
Note the dist inction between the severity and the seriousness of an AE.  A severe event is not 
necessarily an SAE.  For example, a headache may be severe (interferes significantly with patient's usual function) but would not be classified as serious unless it met one of the criteria for SAEs, listed above. 
8.2.3 Relationship to Study Drug  
The Investigator’s assessment of causality must be provided for all systemic and skin AEs 
(serious and non- serious).  An Investigator’s causality assessment is the determination of 
whether t here exists a reasonable possibility that the investigational product caused or 
contributed to an AE.  If the Investigator’s final determination of causality is unknown and the Investigator does not know whether or not the investigational product caused the event, then the event will be handled as “related to investigational product” for reporting purposes.  If the 
Investigator's causality assessment is "unknown but not related to investigational product", this should be clearly documented on study records.  
In addition, if the Investigator determines an SAE is associated with study procedures, the Investigator must record this causal relationship in the source documents and CRF, as appropriate, and report such an assessment in accordance with the SAE reporti ng requirements, 
if applicable.  
After careful medical consideration, the Investigator will evaluate the relationship of each AE to study drug applying the following definitions:  
Probably Related:  An AE that is likely due to the use of the study drug.  The relationship in 
time may be suggestive.  An alternative explanation is less likely, e.g., concomitant drug(s), concurrent disease(s).  
Possibly Related:  An AE that may or may not be due to the use of the study drug.  The relationship in time is reasonable; therefore, a causal relationship cannot be excluded.  An alternative explanation is inconclusive, e.g., concomitant drug(s), concurrent disease(s).  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 37 of 69 
 Not Related:  An AE that is judged to be clearly due only to extraneous causes (disease, 
environment, etc.).  The cause must be noted on the AE CRF page.  
8.3 Serious Adverse Event Definitions  
A serious adverse event (SAE) or reaction is any untoward medical occurrence that at any dose:  
• Results in death;  
• Is life -threatening (immediate risk of death); 
• Requires inpatien t hospi[INVESTIGATOR_1081]; 
• Results in persistent or significant disability/incapacity; or  
• Is a congenital anomaly/birth defect.  
Important medical events that may not result in death, be life -threatening, or require 
hospi [INVESTIGATOR_12475], based upon appropriate medical judgment, they 
may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.  
Definition of disability: A substa ntial disruption of a person’s ability to conduct normal life 
functions. 
Life-threatening SAE: Any AE that places the patient, in the view of the Investigator, at 
immediate risk of death from the reaction as it occurred (i.e., it does not include a reaction that  
had it occurred in a more severe form, might have caused death).  
Hospi[INVESTIGATOR_059]: AEs re ported from clinical trials associated with hospi[INVESTIGATOR_253306].  Hospi[INVESTIGATOR_4592]:  
• Rehabilitation facilities; 
• Hospi[INVESTIGATOR_4593]; 
• Respi[INVESTIGATOR_4594] (e.g., caregiver relief);  
• Skilled nursing facilities; 
• Nursing homes;  
• Routine emergency department admissions; or  
• Same day surgeries (as outpatient/same day/ambulatory procedures).  
Hospi[INVESTIGATOR_4595] a precipi[INVESTIGATOR_2505], clinical AE is 
not in itself an SAE.  Examples include: 
• Admission for treatment of a preexisting condition not associated with the development of a new AE or with a worsening of the preexisting condition (e.g., for work- up of 
persistent pre -treatment lab abnormality);  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 38 of 69 
 • Social  admission (e.g., patient has no place to sleep);  
• Administrative admission (e.g., for yearly PE); or  
• Pre-planned treatments or surgical procedures that have been noted in the baseline 
documentation for the entire protocol and/or for the individual patient. 
Pregnancies, though not expected in this subject population, are not  reported as SAEs.  
Pregnancy follow -up should describe the outcome of the pregnancy, including any voluntary or 
spontaneous termination, details of the birth, the presence or absence of any congenital 
abnormalities, birth defects, maternal or newborn complications and their relation to the study treatment.  
Unexpected Adverse Events  
An unexpected AE is any AE, the specificity or severity of which is not consistent with the current Investig ator brochure; or if an Investigator brochure is not required or available, the 
specificity or severity of which is not consistent with the risk information described in the general investigational plan or elsewhere in the current application, as amended. “Unexpected,” as used in this definition, refers to an AE that has not been previously observed (i.e., is not included in the Investigator brochure) rather than an event that is not anticipated based on the pharmacological properties of the pharmaceutical product. 
8.4 Reporting Requirements For Serious Adverse Events  
ALL SERIOUS ADVERSE EVENTS, REGARDLESS OF CAUSE(S) OR RELATIONSHIP TO STUDY DRUG MUST BE REPORTED IMMEDIATELY TO THE SPONSOR BY [CONTACT_253328].  
8.4.[ADDRESS_308148] Information  
Pete Schmidt, MD, MSc  
Phone /fax: 510- 745-[ADDRESS_308149] 
be made immediately, irresp ective of the extent of available AE information.  This timeframe 
also applies to additional new information (follow -up) on previously forwarded SAE reports.  
The Investigator must complete the SAE Report Form and send it along with other relevant 
source documents to the medical monitor within 24 hours.  For all SAEs, the Investigator is 
obligated to pursue and provide information to the medical monitor in accordance with the 
timeframes for reporting specified above.  The Investigator (or a physician on the investigational 
staff) must provide relationship to study drug as soon as possible and sign the SAE forms.  The Investigator must also provide any relevant information regarding the SAE and respond to requests for follow -up in a timely manner.  All SAEs will also be reported on the AE CRF page 
and CM administered in association with the SAE will be documented on the CRF. 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
[ADDRESS_308150] dose of study drug(s) , it must be reported immediately to the sponsor in the 
same way as the SAEs occurring during the study.  
8.4.[ADDRESS_308151] be followed up until resolution or, in the Investigator’s opi[INVESTIGATOR_1649], a stable condition is reached, or until the patient is lost to follow up.  Based on the medical judgment of the Investigator, all non- serious systemic and skin AEs will be followed until [ADDRESS_308152] visit.  All non -resolved, non- serious systemic and  skin AEs beyond such date will be 
recorded as “ongoing” without further follow up.  
 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
[ADDRESS_308153] CRFs will 
be supplied. CRFs are produced, stored electronically, a nd are available to the designated study 
team members. Each CRF is reviewed and signed by [CONTACT_978]. The final signed CRFs are provided to the Sponsor on CD.
  
 
9.2 Database Management and Quality Control  
Study auditing, data entry, verification and validation of the database, and subsequent analysis 
will be performed by [CONTACT_253329]'s Clinical Research and Development, Clinical Pharmacology, Statistics, and Regulatory Compliance Departments or  the sponsor’s 
representatives for these functions according to current GCP requirements.  In addition, computerized data entries wi ll be checked against paper CRF  if used.  If electronic CRFs are 
used, the system will meet all GCP /ICH -R requirements for database integrity, including 
21 CFR , Part 11. 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 41 of 69 
 10 STATISTICAL METHODS AND DATA ANALYSIS  
10.1 Sample Size Considerations  
No formal sample size calculation was  performed.   In previous studies of Zosano Pharma 
transdermal products  in healthy  volunteers, a sample size of 24 was sufficient to provide 
directional information on tolerability, as well as adequate  information on pharmacokinetics , and 
comparative pharmacokinetics for various regimens.  
10.2 Demographics and Baseline Characteristics  
Demog raphics and baseline characteristics will be summarized descriptively.  
10.3 Analysis Population and Handling of Drop -Outs  
All subjects who receive any amount of study drug will be included in the safety analyses  (Safety 
Population) .  The PK population will incl ude a ll subjects who receive any amount of study drug 
and for whom the PK profile can be adequately characterized .  Drop -outs within a 24- hour 
period are not anticipated; however should they occur prior to [ADDRESS_308154] with samples analyzed using each assay.  
• C
max - maximum observed plasma concentrations  
• Tmax - time to maximum concentration  
• AUC 0-t - the area under the plasma concentration time profile from hour [ADDRESS_308155] 
detectable concentration at time t determined by [CONTACT_39441].  
• AUC 0-30min - the area under the plasma concentration time profile fro m minute 0 to 
minute 30 determined by [CONTACT_39441]. 
• AUC 0-60min - the area under the plasma concentration time p rofile from minute 0 to 
minute 6 0 determined by [CONTACT_39441]. 
• AUC 0-120min - the area under the plasma concentration time p rofile from minute 0 to 
minute 120 determined by [CONTACT_39441]  
• k - apparent elimination rate constant will be estimated by [CONTACT_253316]-transformed plasma concentrations durin g the terminal log -linear decline phase.  
• t1/2 - apparent half -life (t 1/2) values will be calculated as 0.693/k.  
• AUC 0-inf - the AUC value extrapolated to infinity will be calculated as the sum of AUC t, 
and the area extrapolated to infinity, calculated by [CONTACT_3433] e concentration at time t (C t) divided 
by k.  
• Frel -  bioavailability relative to each treatment group  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 42 of 69 
 PK parameters (C max, Tmax, and AUCs) and plasma  and n- desmethyl zolmitriptan  conc entrations 
for M207 and intranasal zolmitriptan will b e summarized using descriptive statistics (arithmetic 
and geometric mean, standard deviation, coefficient of vari ation, minimum, maximum, and 
median)  as applicable.  Individual and mean plasma zolmitriptan  and n- desmethyl zolmitriptan  
concentrations as a function of time foll owing M207 patch administration and intranasal 
zolmitriptan administration will be plotted by [CONTACT_3148].   Calculati on of T max will start from the 
time of study drug administration.  Further details on the analysis of PK parameters can be found 
in the statistical analsyis plan.  
10.[ADDRESS_308156] current version of Medical Dictionary for Regulatory 
Activities (MedDRA®) available at Celerion  and summarized by [CONTACT_253330] (TEAE) and the number of TEAEs reported. A by -subject AE data listing including verbatim term, coded term, treatment, severity, 
and relationship to treat ment will be provided.  
Concomitant medications will be listed by [CONTACT_253331] (WHO) drug dictionary available at Celerion.  
Scores from the investigator skin assessment of the ap plication  sites at [ADDRESS_308157]-dose will also be provided by [CONTACT_253332], heart rate, PR interval, QRS interval, QT,  and QTcF  (Fridericia’ s formula correction ). 
All safety data will be listed by [CONTACT_253333], separate listings of all abnormal laboratory findings will be provided, and clinically significant abnormalities will be recorded as AEs.  
10.[ADDRESS_308158] following removal of each of the patches.  In that case, a description of the disposition of the remaining drug will be presented.  The results from analysis of residual zolmitriptan  on the sk in and the residual zolmitriptan  on the 
used patches will provide a basis for the calculation of the total amount of drug delivered from each treatment.  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 43 of 69 
 11 ADMINISTRATIVE PROCE DURES  
11.1 Changes to the Protoc ol 
Any change or addition to the protocol requires a written protocol amendment initiated and 
approved by [CONTACT_456], Zosano Pharma and the IRB/ IEC and any applicable regulatory 
authority.  
Amendments of an administrative nature do not require formal protocol amendments or approval by [CONTACT_1201]/ IEC, but the IRB/ IEC must be informed in writing of such administrative changes.  
Examples include changes in the staff used to monitor the trial, editorial corrections and clarifications.  
11.2 Investigator Reporting Respon sibilities to the Independent Ethics Committee and 
Other Agencies  
The Investigator mus t promptly report to the IRB all changes in the research activity and all 
unanticipated problems involving risk to human patients or others.  This includes all SAEs  (as 
required by [CONTACT_1201])  that have occurred at the study site and all study -related SAEs that have 
resulted in an expedited safety report to regulatory authorities (serious, unexpected SAEs possibly or probably related to study drug).  Concurrently, the Investi gator must send 
documentation to the Sponsor of such IRB notification.  The Investigator must not make any changes in the research without IRB approval, except where necessary to eliminate apparent immediate hazards to human patient . 
11.3 Withdrawal and Study Termination  
Subjects will be informed that they are free to withdraw from the study at any time.  The Investigator, the Investigator in consultation with the Medical Monitor, or the Medical Monitor may exercise his/her medical judgment to terminate a participant’s participation in the study due to clinically significant changes in any clinical or laboratory parameter (See Section  4.3).  
Zosano Pharma r eserves the right to terminate the study at any time.  All data normally collected 
at completion of the study must be collected either at the time of the subject’s early termination, or on or before the scheduled study close out. Subjects with ongoing AEs at termination will be followed until all significant changes have resolved or become medically stable.  
11.[ADDRESS_308159] access to source da ta/documentation. 
The sponsor's representatives will monitor the study at all stages of study conduct from inception to completion in accordance with current GCPs /ICH -R and a study monitoring plan.  This 
monitoring will be in the form of site visits and other communication and will include review of original source documents and CRF .  The sponsor's monitor or representative will notify the 
principal Investigator [INVESTIGATOR_56670].  The frequency of these visits will depend u pon the progress of the study, and will include monitoring to assess facilities, 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
[ADDRESS_308160] obtain written permission from Zosano Pharma before destroying any study documents. 
11.6 Publicaton Policy  
All information concerning Zosano Pharma operations, patent applications, formulas, 
manufacturing processes, and bas ic scientific data  provided by [CONTACT_253334], are considered confidential and remain the sole property of Zosano Pharma. 
It is understood by [CONTACT_253335] M207, and therefore may disclose this information as required 
to other Zosano investigators, appropriate international regulatory agencies, or others.  In 
agreeing to parti cipate in this study, the investigator understands that he/she has an obligation to 
provide complete test results and all data developed during this study to Zosano  Pharma.  Zosano 
Pharma requires that permission to publish details of this study must be obtained in writing  by 
[CONTACT_253336]/or 
institution.  
11.[ADDRESS_308161] an inspection (during the study or even after its completion).  If an inspection is requested by a regulatory authority, the investigator must inform Zosano Pharma immediately that this request has been made.  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 45 of 69 
 12 REFERENCES  
Dahlöf, C, Solomon G. The burden of migraine to the individual suffer: a review. Eur J Neurol . 
1998;5:  525–33. 
Guidance for Industry: Migraine: Developi[INVESTIGATOR_253307]. 2014 
Hochberg  Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika.  
1988;75:800- 2. 
Lipton R, Scher A, Kolodner K, et al. Migraine in the [LOCATION_002]: epi[INVESTIGATOR_253308]. Neurol . 2002;58(6):885- 94. 
Rapoport A, Ramadan N, Adelman J, et al. Optimizing the dose of zolmitriptan (Zomig, 
311C90) for the acute treatment of migraine. A multicenter, double -blind, placebo- controlled, 
dose range -finding study.  Neurology . 1997;49(5):1210- 18. 
Schoenen J, Caekebeke P, Louis, G, et al. An open study to investigate the absorption and 
tolerability of oral 311C90 and to obtain a preliminary indication of efficacy in migraine 
patients. Proceedings of the 10th Migraine Trust Symposium. New advances in headache 
research.  1994;vol. 4:11- 2. 
Seaber E, Peck R, Smith D, et al. The absolute bioavailability and effect of food on the 
pharmacokinetics of zolmitriptan in healthy volunteers. Br J Clin Pharmacol . 1998 
Nov;46(5):  433–9.  
Visser W,  Klein K, Cox R, et al. 311C90, a new central and peripherally acting 5- HT 1D receptor  
agonist in the acute oral treatment of migraine: a double -blind, placebo- controlled, dose -range 
finding study. Neurology. 1996 Feb;46(2):522 -6. 
 
Zosano Pharma Corporation  Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 46 of 69 
 13 SCHEDULE OF ASSESSME NTS  
Assessment*  Screening 
Visit**  Admission/
baseline  Dosing Visit***  End of 
Study/Early 
Termination  
 
Screening  Day Prior 
to first 
Dose  Pre-
dose 0 
mn 2 
mn 5 
mn 10 
mn 15 
mn 20 
mn 30 
mn 45 
mn 60 
mn 90 
mn 2 
hr 4 
hr 8 
hr 12 
hr 24 
hr Approximately 
48 hours after 
comple tion of all 
procedures on 
final dosing day  
Informed consent  X                   
Medical history/  
demographics  X                   
Concomitant 
medications                     
Physical exam  X               X   X 
Serum pregnancy test  X X                 X 
Height  X                   
Weight  X                  X 
Confirm eligibility  X X X                 
Clinical laboratory 
tests chemisty , 
hemat ology , UA)  X                  X 
Serology  X                   
Urine Drug & Alcohol 
Testing  X X                  
Collect PK samples    X  X X X X X X X X X X X X X X  
Study drug 
administration     X                
Vital signs  (inclusive 
of temperature at 
screening , admission , 
and end of study/or 
ET only ) X X X    X     X  X X  X   
 
X 
ECG  X  X     X         X  X 
Remove and retain 
(freeze) patches            X          
 
Zosano Pharma Corporation  Protocol No. CP -2019-002v1 
 
15 April 2019 Confidential  Page 47 of 69 
 Assessment*  Screening 
Visit**  Admission/
baseline  Dosing Visit***  End of 
Study/Early 
Termination  
 
Screening  Day Prior 
to first 
Dose  Pre-
dose 0 
mn 2 
mn 5 
mn 10 
mn 15 
mn 20 
mn 30 
mn 45 
mn 60 
mn 90 
mn 2 
hr 4 
hr 8 
hr 12 
hr 24 
hr Approximately 
48 hours after 
comple tion of all 
procedures on 
final dosing day  
Nasal Assessment for 
Treatment D only    X                 
Investigator skin 
assessment of the 
application sites  ****    X        X  X    X  X  
X 
Swabbing             X          
Record Adverse 
events                     
* When multiple procedures are scheduled for the same time point, PK samples will be taken at th e protocol assigned time point within plus or minus [ADDRESS_308162] hour and within plus or  minus  5 minutes of the specified time p oints after one hour .  The other measurements (i .e., vital signs, ECG , 
skin assessments ) will be taken before or after the protocol -specified time point within  an interval of plus or minus 5  minutes.  
** Screening Visit –  Up to 30 days prior to the  Admission /Baseline  visit.  
*** The washout peri od following each dose must be a minimum of [ADDRESS_308163] removal of the second patch (in each treatment A, B, and C dosing period)  until the 
next dose  is administered . 
**** Investigat or skin assessment at 30 minutes to be completed within one minute of M207 removal . 
 
 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April  2019 Confidential  Page 48 of 69 
 APPEN DIX 1: M207  PATCH ADMINISTRATION  
 
TABLE OF CONTEN TS 
I. INTRODUCTION  
II. GENERAL  DESCRIPTION  
1. The Patch 
2. The Applic ator 
3. Storage 
III. PRECAUTIONS AND OTHER  NOTE S  
IV. INSTRUCTIONS  FOR USE  
1. Before You Apply the Patch 
2. Opening the Packagi ng 
3. Attaching the Patch Ri ng to the Ap plica tor and Ap plying the Patch 
4. After Applying the Patch 
5. Removing the Patch 
  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April  2019 Confidential  Page 49 of 69 
 I. INTRODUCTION 
The M07 patche s and a s pecially designed applic ator are m ade by [CONTACT_253337].  This U ser’s 
Guide provides instructions for the clinical  staff on h ow to apply patche s to subjects.  The 
patche s look lik e round a dhesive Band-Aids and ha ve study drug on ti ny metal points on one 
side.  Patche s are applie d to the subject’s skin usi ng a spring-loaded applicator s pecially  designed 
for these patches.  Each  patch is us ed only once.  The applicat or can be  reused. 
II. GENERAL DESCRIPTION  
The M207 (Zolmitriptan  Microneedle System ) has two parts: a patch at tached to a plastic 
suppor ting ring, and an a pplicat or. 
1. The Patch: The patch comes attached to a plastic  suppor ting ring that allows you to attach it 
to the applicator.  W hen you apply the patch t o the skin, the patch stays on the skin a nd the 
plastic  ring st ays on the applicat or and is la ter thrown aw ay. 
 Top Bottom 
 
There is study drug on the shiny metal on the sticky side of the patch.  Y ou can touch t he 
suppor ting plastic  ring, but do not touch the sticky s ide of t he adhesive patch or the shiny met al 
pi[INVESTIGATOR_253309].  Touching this may damage the patch. 
Patch 
backing  
Plastic support ring 
Shiny metal 
surface  
Plastic 
support ring 
Adhesive 
Patch with 
drug 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
[ADDRESS_308164] unge r pus hes the patch out of the 
support  ring and applies  it to the skin. 
3. Storage of  Supplies (patches an d applicators): 
Room temp erature storage: Store the patches in their pouches and cup s at room temperature.  
Store the applic ator at room temperature in its  box between us es. 
III. PRECAUTIONS  AND OTHER  NOTES 
Lotions, Ointments, or Powders: Ensure no  lotions, ointments, or powders have been 
applied  to th e patch app lication sites [ADDRESS_308165] ying the patches. 
Was h Hands: Always wash you r hand s before app lying a patch. 
 

 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April  2019 Confidential  Page 51 of 69 
 IV. INSTRUCTIONS FOR  USE 
1. Before You A pply the Patch 
• Check the skin at the upper arm  to be sure that it is  not irritate d from rash, inflammati on, 
redness, or other  skin problems such as  cuts or open wounds.   In addition, the application 
area must be free of tatoos , scars, birthmarks, and/or  any skin abnormalities.  
• Clean the the skin area upper arm where the patches will be applied with an  alcohol wipe.  
Only wipe with alcohol prior to the first patch application for each dose . 
2. Opening the  Foil Pouch (Treatment A) or  Cup (Treatment B and C)  Containing the 
Patch and  Plastic Ring 
Patch and Ring in Packa ge 
Pouch:       Cup:  
 
 
  
• Each patch is  individually  sealed in its  own pr otective outer foil pouch or cup.  
• DO NOT USE the patch if its  cup has a hole in it,  has already been torn open, or is 
otherwise damaged. 
• With the tab pointing towards you, t o open  the foil pouch or  cup, lay the pouch or  cup flat 
with pri nted side up.  Using the notches provided, slowly  peel ba ck the top layer of the 
cup to open with “This side up” facing up.  If the cup is  difficult to ope n, yo u can use  
scissors to cut along t he dotted line.  
 

 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April  2019 Confidential  Page 52 of 69 
 Pouch:        Cup:  
                                       
 
• Leave the patch  on the bottom side of the cup.  You can t ouch the white plastic patch ri ng 
with your fi ngers.  Ho wever, do not touch  the patch  or shiny metal surface of the patch  
with your fingers.  This may da mage or contaminate the patch. If you acci dentally touch  
the shiny metal surface with your finger, return the patch to t he original pouch or cup , 
write the date on the pouch or  cup, and start  over with a n ew patch. 
Pouch:        Cup:  
 
                                   
 

 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April  2019 Confidential  Page 53 of 69 
 3. Attaching the Patch Ring to th e Applicator, and Applying the Patch to th e Skin 
(see Figure 1) 
 
1. Prepare the patch and applicator  
o Open the applicat or box and remove the applica tor from its box 
o Ensure the applicat or is s et to ‘1’.  The applicator is ready to attach a patch 
when in the number ‘1’ position.  If t he num ber ‘2’ is showi ng in t he window, 
change it to ‘1’ by [CONTACT_253338]. 
o Ensure the patch is sitting shiny metal side down.  If not, gently pi[INVESTIGATOR_253310].  The shiny metal side should now be face down.  
2. Attach the patch and ring to the applicator by [CONTACT_253339].  You will likely 
hear or feel a “click.” The patch is now attached to the applicator.  
3. Holding the bottom half of the applicator with one hand, unlock  the applic ator by 
[CONTACT_253340] “2” position.  
The patch and applicat or are now  ready for applicati on. 
4. Ensure the num ber shows ‘ 2’ in t he wi ndow, i ndicating the applica tor is unlocked.  If 
not, go b ack t o step 4 to change i t from  ‘1’ to ‘2’. 
5. Place  the applic ator on the skin a nd push t he applic ator against the skin. 
6. When you ha ve pus hed a gainst the skin h ard en ough , you will h ear the plunger push t he 
patch fr om the ring onto the skin.  C ontinue  to hold the applica tor down a gainst the skin 
for [ADDRESS_308166]’s skin for the duration assigned in accordance with the 
protocol  treatment assignment  (30 minutes) . 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April  2019 Confidential  Page 54 of 69 
 Figure 1 : M207 Patch Application  
 
 
 
 
 1. Snap pat ch-ring assembly on to 
applicator 
 
 
 2. Twist applicator cap clockwise from  
Position [ADDRESS_308167]’s  skin f or the durat ion assigned in ac cordance wi th the protocol. 
Before applying the second patch, r emove the used plastic  support ring from the applicator and 
discard it .  Use  your finger to pull th e used patch ring off  the applicat or.  Throw away the patch 
ring. 
 
 
5. Removing the Patch 
After the appropria te assigned time of patch  applicat ion, pe el the edge of the patch back and 
remove the patches from the subject’s skin as  you would r emove a Band- Aid.  R efer to 
Appendix 3 for handling and processing of  used patch es, storage , and r eturn instructions. 

 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April  2019 Confidential  Page 57 of 69 
 APPEN DIX 2: ZOLMITRIPTAN  PK SAM PLE HANDL ING  
1. Plasma Zolmitriptan  Sample Collection 
Approximately [ADDRESS_308168] .    
The blood samples will be maintained in a chilled ice bath prior to centrifuging.  The samples 
will be centrifuged  for 10 minutes at  4○C at 2000 x g and the aliquots will be placed in the 
freez er within 60 minutes of sample collection.  The plasma supernatant will be transferred to 
polypropylene tubes and labeled identically to the original sample container.  Two aliquots will 
be prepared.  Plasma will be aliquoted into a separate LDPE container s labeled (at minimum) 
with the study number, subject’s identification number,  date and time  of collection, and analyte 
(zolmitriptan ).  Aliquot [ADDRESS_308169] of the 
plasma  (approximately 1 mL). After processing, the tubes will be sealed and the plas ma will be 
frozen in an upright position (to avoid frozen plasma in the caps) and stored in a - 80 °C  
(+/- 10 °C ) freezer  in an upright position until shipped for analysis.   
Each sample will be labeled or barcoded (at minimum) w ith the study  number, subject 
identification number , actual date and time of col lection, analyte (zolmitripan).  
2. Plasma Zolmitriptan  Sample Shipment 
Securely pack  the frozen samples in Styrofoam freezer  boxe s with s ufficie nt dry ice to ensure the 
samples remain frozen for at least [ADDRESS_308170] shipment, the second set of aliquots 
may be sent  upon approval by [CONTACT_253341] .  The shippi[INVESTIGATOR_253311].  
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April  2019 Confidential  Page 58 of 69 
 APPENDIX 3 : HANDLING  AND PROCESSING OF USED PATCHES AND SKIN 
SWAB S  
Delivery  performance  of M207  patches  is determined  by [CONTACT_253342].   The amounts  of 
zolmitriptan  left on the microneedle array  and skin surface  after  each  application  are compared  
against  the original  coated  amount  on the array,  allowing  total  amount  delivered  or delivery  
efficiency  to be determined  by [CONTACT_253343].   This  Appendix 3  provides  detail ed procedure s for 
used patch  removal  and subsequent  swabbing  of the treated  skin  surface .  The collected  used  
patches  and skin  swabs  (in swab  buffer) will  be shipped  to the site where plasma samples are 
analyzed.   
MATERIALS:   
A. Content  of Used  Patch es and Skin  Swab bing  Kits 
Figure  1 outlines  the materials  provided  by [CONTACT_253344].   The  materials  for both procedures  will be combined  into one kit (for each  
dosing  period)  and designated  as the Used  Patch/Skin  Swab  Kit.  Note  that materials  similar  to 
what  are shown in  Figure  1 may be used  as substitutes . Each  kit contains  materials  (Table  1) to 
collect  from  one dosed  patient:  2 used patches  and two skin  swabbing  for each  dosing  period.    
 
 

 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April  2019 Confidential  Page 59 of 69 
 PROCEDURE:  
USED  PATCH  REMOVAL  PROCEDURE  FROM  SKIN  AND  PROCESSING  
Refer to Figure 1  (above) for material identification and Figure 2 (below) for used patch removal 
procedure.  Note the following procedural highlights:  
1. Do not touch or contaminate the patch -treated skin sites after patch removal.   
2. Since each patient  has two patches applied, remove one patch at a time and  note the skin 
area where the patch was removed for subsequent skin swabbing in Section B .  
3. Try to perform used patch removal and skin swabbing, for the first and second patches , 
within [ADDRESS_308171] used patch.  
 
A minimum  of 80 kits will be provided by  [CONTACT_253345] 80, 8 (10%)  kits are allotted  for 
backups  and 72 are allotted  for 24 subjects  with  3 treatments.   Once  the used patch  collection  and 
skin swabbing  are c ompleted  for all subjec ts, there  should be  in total 144 used patch  vials  and 
144 swab  buffer  vials  to be processed  and shipped  to Syneos  Health.   

 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April  2019 Confidential  Page 60 of 69 
 Table  1. Tally/ Labeling  of Materials  Included  in each  Used  Patch/Skin  Swab  Kit 
Item #  Description  Quantity  Labeling  
1* Orange -cap cryovial with 1 -mL swab buffer  2 #1 to 144 (sequentially) with 
“1-mL Swab Buffer”  
2** Swab buffer vial with 1 dry swab  2 **For Items # [ADDRESS_308172] the following:  
- Subject ID  
- Patc h location, ie, upper arm 
and number or side ( e.g., 1 
and 2, o r left and right )  
- Sample collection date and 
time 
- Protocol number  3 Sterile forceps, individually packaged  2 
4** Used patch collection vial  2 
5 Ziploc bag for Item 4  2 
6 Vial with 4 dry swabs  1 
7 Purple -top 50 -mL tube 2 
8** White tub with yellow lid to contain Items 1 -7 1 
*This  orange -cap cryovial containing buffer will be stored in refrigeration at approximately 0 -4°C and 
removed several hours before swabbing.  
 
Labeling : *Item #1 will be numbered from 1 to 144 by [CONTACT_253341].  ** Items # 2, 4 and 8 will need 
to be labeled prior to use with a minimum of the following: Subject ID, patches  location (upper 
arm), and numbering or position ( e.g., site 1 or 2 or left/right), sample collection date and time, 
and protocol number.  
B. Skin Swabbing After Each Used Patch Removal  
Refer to Figure 1  for material identification and Figure 3  for skin swabbing procedure.  
For each separate patch , the patch-treated skin surface is  swabbed  using  three  polyurethane  
swabs : [ADDRESS_308173] swab  is soaked  in 1.0-mL of  0.05%  Tween  20 (in phosphate  
buffer  saline).   The 0.05%  Tween  20 in phosphate  buffer  saline  is also referred  to as “swab  
buffer”  and shown in Figu re 1, Item  1.  The wetted  swab  is applied  over the skin site by [CONTACT_253346]  (e.g., left to right  and up and down)  and around  
the periphery  of the treatment  site.  Two  additional  swabs,  dry, are applied  sequentially  over  the 
wetted  skin site  using the  same  rolling  motions  to absorb all  residual  buffer.   Make  sure to absorb  
all residual  buffer on the skin since  this is the medium  used to capture  the residual  zolmitrip tan 
from  the skin.  Once used,  all three  swabs  are placed  in the swab  buffer vial  and sent Syneos  
Health  for zolmitriptan  analysis.  
Note the following  procedural highlights:  
1) Cryovials  with  swab  buffer:  1-mL of the swab  buffer aliquot  is contained  in each orange -cap 
cryovial  (Item  #1) and 144 will be sent from  Zosano  and should be stored  at 0-4°C prior  to use.  
Two cryovials  (containing buffer)  are allotted  for each of the two used patch es and should  be 
removed  from  refrigeration  and placed  with Kit sever al hours  before  swabbing.   At least 1 hour  
before  swabbing,  pour the content  of one cryovial  into one swab  buffer vial  with dry swab  
(Item  # 2) and repeat  for the other  set.  Place both swab  buffer  vials  into the Kit tub to keep them 
slightly  upright  as shown in figure  3B. 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April  2019 Confidential  Page 61 of 69 
 2) Start skin swabbing procedure immediately after  patch removal . 
3) Try to complete  used patch removal and skin swabbing, for first and second patch, within 
[ADDRESS_308174] used patch.  
4) Wetted swab should not be drippi[INVESTIGATOR_253312] . Keep 
all swabs clean  until used.  
5) Apply the wetted swab over the treated skin site by [CONTACT_253347]  (back -and-forth) the swab with 
slight pressure in several directions (e.g., left to right and up and down) and around the periphery 
of the treatment site.  Once swabbing is done, place the wetted swab back into the swab buffer vial. 
6) Apply two additional swabs (dry), one at a time, over the wetted skin site using the same rolling motions to absorb all re sidual buffer  on the skin. Once swabbing is done, place both 
swabs into the same swab buffer vi al. 
 

 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April  2019 Confidential  Page 62 of 69 
 C. Packing of Used Patches and Skin Swabs  
Refer to Figure 4  for packing illustration.  Use the Kit tub to pack the used patch vials (2) and 
swab buffer vials (2) collected from each dosed patient.  Pack all tubs in dry ice for shippi[INVESTIGATOR_253313].  
 
 

 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April  2019 Confidential  Page 63 of 69 
 APPENDIX 4:  SHIPPI[INVESTIGATOR_253314]  
1. Unused Patch Collection and Shipment 
Collection:  All unused systems should be stored in their original  pouches or  cups and shippi[INVESTIGATOR_59365], at room temperature until shipment to Zosano Pharma. 
Shipment: All unused systems should be  combined into one shipment and shipped at room 
temperature - upon authorization from Zosano Pharma . 
Shipments should be made via Wor ld Courier using the Zosano Pharma World Courier 
Account  number [ZIP_CODE].  
All returned packages should contain  the statement: “F or research pur poses only.  Not for human 
use.” 
Complete  the Product  Return Form (provided by  [CONTACT_2728]) and include with  each return 
shipment: 
• Insert [ADDRESS_308175] as a 
packi ng sli p. 
• Keep 1 copy in the Regulatory  binder  
• Fax or email one  copy to Zosano Pharma, Lu Liu  ([EMAIL_4879] ) and 
Whitney Halladay ([EMAIL_4880]) , Fax : +[PHONE_5261] , 
Phone : +[PHONE_5262]  
 Unused  Patch shipments to Z osano Pharma should be add ressed to: 
Zosano Pharma 
ATTN: Lu Liu  
Senior D irector, Manufacturing  and Supply Chain  
[ADDRESS_308176] 
Fremont, CA [ZIP_CODE] [LOCATION_003] 
Phone : +[PHONE_5263]  
Fax: +[PHONE_5261] 
 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April  2019 Confidential  Page 64 of 69 
 2. New  Applicator Collection an d Shipment  
Collection: At the completion of  the study, place t he used applica tors back  into the original 
applicator box or equivalent.  Place the applicator boxes into a Ziploc bag and label bag with 
“Used Applicators.”  Place all unused applicators into another Ziploc bag and label bag wi th 
“Unused Applicators.”   Store used and unused applicators at room temperature until shipment to 
Zosano Pharma.  All samples should be shipped in one shipment. 
Shipment:  Securely pack the bags of used and/or unused applicators into suitable boxes 
containing shippi[INVESTIGATOR_179269] (e.g. , Styrofoam “popcorn” or bubble -wrap).  Both used and 
unused applicators may be shipped back to Zosano Pharma at ambient temperature.  
Shipments should be made via Wor ld Courier using the Zosano Pharma World Courier 
Accoun t [ZIP_CODE].  
All returned packages should contain  the statement: “F or research pur poses only.  Not for human 
use.” 
Complete the Product Return Form (provided by [CONTACT_2728]) and include with  each return 
shipment: 
• Keep 1 copy in the Regulatory  binder 
• Place another copy of the Form in a Ziploc back and place the Ziploc bag inside the 
shippi[INVESTIGATOR_7788]; this copy  will be used as the packing slip for the shipment.   
• Fax or email one  copy to Zosano Pharma, Lu Liu  ([EMAIL_4879] ) and 
Whitney Halla day ([EMAIL_4881]) , Fax : +[PHONE_5261], 
Phone  +[PHONE_5262]  
 
Applicator shipments to Z osano Pharma Corporation : 
Zosano Pharma Corporation  
ATTN: Lu Liu  
Senior  Direct or, Manufacturing  and Supply  Chain  
[ADDRESS_308177] 
Fremont, CA [ZIP_CODE]  [LOCATION_003] 
Phone : [PHONE_5264]- 745-1289  
Fax: +[PHONE_5261] 
 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
15 April  2019 Confidential  Page 65 of 69 
 APPENDIX  5: DECLARATION OF HELSINKI 
 
WORLD M EDICAL ASSO CIATION DECLARATION 
OF HELSINKI Ethical Principles for Medi cal Research 
Involving Human Sub jects 
 
Adopted by [CONTACT_941] 18th WM A Gener al 
Assembly 
Helsinki, Finland, Jun e [ADDRESS_308178] the health of the people.  The physician’s 
know ledge and consci ence are  dedicat ed to the fulfill ment of this du ty. 
The Declaration of Geneva of the World Medical Associati on bi nds the physician with the  words, 
“The he alth of  my patient will be  my first consideration,” and the International C ode of Medical  
Ethics de clares that, “A phy sician shall act  only  in the patient’s interest when providing medical  
care w hich m ight have the effect of weakeni ng the physical and mental condition of the patient.” 
Medical pr ogress is based on research that ultimately must rest in part on e xperimentation 
involving hum an subjects. 
In medical  research on hu man subjects, considerations  related to the well being of the hum an 
subjects should ta ke precedence over  the interests of s cience  and society. 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
[ADDRESS_308179], the confidentiality  of the 
patient’s information and to m inimize the impact of the study on the subject’s physical a nd 
mental integrity and on the personality of t he subject. 
In any research on hum an beings, each p otential s ubject must be adequately informed to the 
aims, me thods, sources of fundi ng, any possi ble conflic ts of interest, institutional affilia tions of 
the researcher, the anticipa ted be nefits and pote ntial risks  of the study and the discomfort it may 
entail.   The subject should be  informed of t he right to abstain f rom parti cipation in t he study or to 
withdraw  consent to partici pate a t any time without reprisal.  A fter ensuring that the subject has 
unde rstood t he information, the physician  should  then obtain the  subject’s freely given informed 
consent, preferably in writing .  If consent cannot  be obtained in writing , non-written consent 
must be formally documented and wit nessed. 
When obtaining informed consent for the research pr oject the physician s hould b e partic ularly 
cautious if t he subject is in a de pendent relations hip with the  physician or  may consent under 
duress.  In that case the informed consent should be obtai ned by a well-informed physician w ho 
is not engaged in t he investigation and who is completely independent of this relationship. 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
[ADDRESS_308180] obtain  that assent in addition to 
the consent of the legally authorized repr esentat ive. 
Research on i ndividuals fr om whom it is no t possible to obtain c onsent, including pr oxy or 
advance cons ent, should be done only  if the physical/mental condition that prevents obtaining 
informed consent is a ne cessary characteristic of the research populat ion.  T he specific reasons 
for involving research s ubjects with a  condition that renders them unable to give informed 
consent should be  stated in the experimental protocol for consideration and approval of the 
review commi ttee.  The protocol should state  that consent to remain in t he research should be  
obtai ned as soon as possible from  the individual or a l egally authorized surrogate. 
Both a uthors and publis hers have ethical  oblig ations. In publication of the results of research, the 
Investigators are oblige d to preserve the accuracy  of the results.  Negative as well as positive 
results should be  published or otherwise  publicly  availa ble.  S ources of funding, institutional 
affiliati ons and any possi ble conflic ts of interest should be  declared in t he publicati on.  R eports 
of experimentation not  in accordance with the principles laid down in t his Declaration should not  
be accepted for publicati on. 
ADDIT IONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH 
MEDICAL CARE. 
The physician  may combine medical r esearch with medical car e, only to the extent that the 
research is j ustified b y its potential prophylactic, diagnostic or therapeutic value.  When medical 
research is com bined with medical car e, additional  standards apply to protect the patie nts who 
are research s ubjects.  
The benefits, risks, bur dens and effe ctiveness of a new  method s hould be  tested against those of 
the best current prophylactic,  diagnostic  and therapeutic methods.  T his does not exclude the use 
of placebo, or n o treatment, in studies where n o proven  prophylactic, diagnostic or therape utic 
method exists.  
At the conclusion of the study, every patient entered into the study should b e assured of access to 
the be st-proven prophylactic, diagnostic  and therapeutic methods identified by [CONTACT_1758]. 
The physician  should f ully inform the patient which a spects of the care are related to t he 
research.  The refusal of  a pat ient to participate in a  study must never interfer e with the patie nt-
physician r elationship.  In the treatment of a pati ent, where proven prophylactic, diagnostic and 
therap eutic methods do not exist  or ha ve been i neffective, the physician, w ith informed consent 
from the patient, must be free to use unpr oven or new prophylactic,  diagnostic  and therapeutic 
measures, if in  the physician’s judgment it offers  hope of saving life, re-establishing he alth or 
 
Zosano Pharma Corporation   Protocol No. CP -2019-002v1 
 
[ADDRESS_308181] of re search, 
designed to evaluate their safety and efficacy. In all c ases, new information s hould be  recorded 
and, w here appropriate, publis hed.  The other relevant guidelines of this De claration should be  
followed. 